Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Daniel ShepshelovichAmanda R TownsendOsvaldo Espin-GarciaLidija LatifovicChris J O'CallaghanDerek J JonkerDongsheng TuEric ChenEric MorgenTimothy Jay PriceJeremy ShapiroLillian L SiuMichiaki KuboAlexander DobrovicMark J RatainWei XuTaisei MushirodaGeoffrey LiuPublished in: Cancer medicine (2018)
The FCGR2A genotype was associated with efficacy but not with toxicity in wild-type KRAS, cetuximab-treated colorectal cancer patients. FCGR3A genotype may modulate the relationship between FCGR2A polymorphism and outcome. FCGR2A is a promising biomarker for clinical management for these patients.
Keyphrases
- wild type
- metastatic colorectal cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical trial
- oxidative stress
- peritoneal dialysis
- study protocol
- squamous cell carcinoma
- stem cells
- randomized controlled trial
- locally advanced
- patient reported outcomes
- free survival
- cell therapy
- smoking cessation